£13.0M
The financing round was co-led by Ananda Impact Ventures and BGF to accelerate platform and product development.
Meltwind acts as the due diligence and portfolio management team for angel investor Jonathan Milner, supporting early-stage life sciences companies.
The financing round was co-led by Ananda Impact Ventures and BGF to accelerate platform and product development.
The funding round was led by Heal Capital and will support team expansion and product development.
"Healthcare touches each and every one of us and the recent pandemic has highlighted that at a global level. It showed the need to bring healthcare closer to people’s homes and that we need to leverage many of the recent innovations in digital health and consumer biotech to capture as many data points about human health as possible. This will transform our understanding of the human body and our approach to disease detection and management. At Sanome we are working toward developing multiple at home health tools to drive disruption within the healthcare landscape to benefit each one of us"
The funding round was led by nChain and Cambridge Innovation Capital.
"Businesses have realised that advanced analytics and rapid innovation is the key to building competitive advantage in a data-driven world, so where billion row queries that took hours were once acceptable, the market now demands trillions of rows and speed-of-thought results. Aside from performance and scale, database technology needs to be built with the future of the connected world in mind – providing flexibility and cost predictability, even as the demands for big data continues to grow."
The seed round was led by Meltwind and Start Codon to accelerate in vivo proof-of-concept studies.
"Incorporation of our technology into ADC products will accelerate and energise the important transition away from the 'one size fits all' approach currently being pursued in ADC development, resulting in novel products with a competitive and differentiated profile. The platform has the power to unlock the development of a new generation of powerful and well-tolerated drugs, which have been so far inaccessible to many cancer patients."